Advanced Search
Contact | Corporate | Help

A Phase I Study of the Safety and Immunogenicity of rgp120/HIV-1IIIB Vaccine in Healthy Adult Subjects (NOTE: Study Extended ONLY for Subjects Who Have Previously Received rgp120/HIV-1IIIB or rgp120/HIV-1MN on VEU 006 or VEU 006 Rollover Study)

Sponsors:
  • National Institute of Allergy and Infectious Diseases (NIAID)
  • Genentech
Phases:
  • Phase I
IndicationsAcronym:
  • HIV Infections
Age Groups:
  • Adult
Gender:
Both
Names:
  • Biological: rgp120/HIV-1IIIB
  • Biological: rgp120/HIV-1MN
Enrollment:
28

Additional information about NCT00001020.


SourceSolution © 2008-2012